CITY-RBP4 is an RNAi therapeutic candidate designed to provide potent and durable suppression of RBP4, a clinically supported target in Stargardt disease City’s second program to advance into the clinic, demonstrating strong momentum across the pipeline CAMBRIDGE, Mass., Nov.
Preclinical data supporting CITY-TFR2 for anemia of chronic disease to be presented in a poster session CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi)
CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that management will participate in the following investor conferences in
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the closing of its upsized initial public
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) (“City” or “City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the pricing of its upsized initial public
CAMBRIDGE, Mass.--( BUSINESS WIRE)--City Therapeutics, Inc. (City), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced the appointments of Keith Regnante, MBA, as Chief Financial Officer, and Mary Beth DeLena, J.D., as
Viking Global Investors and Sofinnova Investments join a strong syndicate of existing investors including ARCH Venture Partners, Fidelity Management & Research Company and Invus Proceeds to accelerate the company’s RNAi engineering platform and pipeline, including ongoing Phase 1 clinical trial of
Data demonstrate potent, durable RNAi-mediated silencing of retinol binding protein 4 (RBP4) with reduced toxic retinoid accumulation, a key driver of the rare inherited retinal disease CAMBRIDGE, MA, May 6, 2026 – City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA